×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NYSE:ZTS

Zoetis Stock Forecast, Price & News

$174.61
+5.44 (+3.22%)
(As of 06/24/2022 06:40 PM ET)
Add
Compare
Today's Range
$171.39
$174.68
50-Day Range
$155.97
$187.78
52-Week Range
$154.18
$249.27
Volume
3.26 million shs
Average Volume
2.41 million shs
Market Capitalization
$82.18 billion
P/E Ratio
40.05
Dividend Yield
0.74%
Price Target
$229.75
30 days | 90 days | 365 days | Advanced Chart

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock Forecast (MarketRank)

Overall MarketRank

2.76 out of 5 stars

Medical Sector

46th out of 1,411 stocks

Pharmaceutical Preparations Industry

15th out of 672 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
Zoetis logo

About Zoetis (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock News Headlines

Zoetis (NYSE:ZTS) Hits New 12-Month Low on Insider Selling
A Look At The Fair Value Of Zoetis Inc. (NYSE:ZTS)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
12,100
Year Founded
2012

Company Calendar

Ex-Dividend for 6/1 Dividend
4/20/2022
Last Earnings
5/05/2022
Dividend Payable
6/01/2022
Today
6/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$229.75
High Stock Price Forecast
$264.00
Low Stock Price Forecast
$208.00
Forecasted Upside/Downside
+31.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
9 Analysts

Profitability

Net Income
$2.04 billion
Pretax Margin
32.04%

Debt

Sales & Book Value

Annual Sales
$7.78 billion
Cash Flow
$5.68 per share
Book Value
$9.60 per share

Miscellaneous

Free Float
470,064,000
Market Cap
$82.18 billion
Optionable
Optionable
Beta
0.77

Social Links















Zoetis Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Zoetis stock.
View analyst ratings for Zoetis
or view top-rated stocks.

What is Zoetis' stock price forecast for 2022?

9 analysts have issued 1 year price objectives for Zoetis' shares. Their ZTS stock forecasts range from $208.00 to $264.00. On average, they predict Zoetis' stock price to reach $229.75 in the next year. This suggests a possible upside of 31.6% from the stock's current price.
View analysts' price targets for Zoetis
or view top-rated stocks among Wall Street analysts.

How has Zoetis' stock performed in 2022?

Zoetis' stock was trading at $244.03 at the start of the year. Since then, ZTS stock has decreased by 28.4% and is now trading at $174.61.
View the best growth stocks for 2022 here
.

Are investors shorting Zoetis?

Zoetis saw a decrease in short interest in May. As of May 15th, there was short interest totaling 4,070,000 shares, a decrease of 17.9% from the April 30th total of 4,960,000 shares. Based on an average trading volume of 2,280,000 shares, the short-interest ratio is currently 1.8 days. Approximately 0.9% of the shares of the company are short sold.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Zoetis
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Thursday, May, 5th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.10. The firm earned $2 billion during the quarter, compared to analysts' expectations of $1.98 billion. Zoetis had a net margin of 26.27% and a trailing twelve-month return on equity of 49.62%. The firm's quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the business earned $1.26 EPS.
View Zoetis' earnings history
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Thursday, May 19th. Stockholders of record on Thursday, July 21st will be paid a dividend of $0.325 per share on Thursday, September 1st. This represents a $1.30 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend is Wednesday, July 20th.
View Zoetis' dividend history
.

Is Zoetis a good dividend stock?

Zoetis(NYSE:ZTS) pays an annual dividend of $1.30 per share and currently has a dividend yield of 0.74%. Zoetis does not yet have a strong track record of dividend growth. The dividend payout ratio of Zoetis is 29.82%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 22.57% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY 2022 earnings guidance on Thursday, May, 19th. The company provided EPS guidance of $4.99-$5.09 for the period, compared to the consensus estimate of $5.16. The company issued revenue guidance of $8.22 billion-$8.38 billion, compared to the consensus revenue estimate of $8.42 billion.

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Ms. Kristin C. Peck, CEO & Director (Age 51, Pay $3.86M) (LinkedIn Profile)
  • Mr. Glenn C. David, Exec. VP and Group Pres of International Operations, Aquaculture, BioDevices & Pet Insurance (Age 50, Pay $1.9M) (LinkedIn Profile)
  • Mr. Wetteny N. Joseph, Exec. VP & CFO (Age 50, Pay $2.91M)
  • Ms. Heidi C. Chen, Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics (Age 55, Pay $1.39M) (LinkedIn Profile)
  • Mr. Roman Trawicki, Exec. VP and Pres of Global Manufacturing & Supply (Age 58, Pay $1.92M) (LinkedIn Profile)
  • Ms. Roxanne Lagano, Exec. VP and Chief HR Officer & Global Operations (Age 57) (LinkedIn Profile)
  • Ms. Wafaa Mamilli, Exec. VP and Chief Information & Digital Officer (Age 55)
  • Mr. Steven Frank, VP of Investor Relations
  • Mr. William Price, VP & Chief Communications Officer
  • Mr. Timothy J. Bettington, Exec. VP and Pres of U.S. Operations & Global Customer Experience (Age 48)

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among Zoetis' employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.87%), Vanguard Group Inc. (7.63%), State Street Corp (4.18%), Bank of America Corp DE (2.71%), Capital World Investors (1.91%) and Polen Capital Management LLC (1.42%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis
.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Capital Research Global Investors, AustralianSuper Pty Ltd, Vanguard Group Inc., 1832 Asset Management L.P., Royal Bank of Canada, Bank of New York Mellon Corp, and Brown Brothers Harriman & Co.. Company insiders that have sold Zoetis company stock in the last two years include Catherine A Knupp, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Roman Trawicki, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis
or view top insider-selling stocks.

Which major investors are buying Zoetis stock?

ZTS stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Arrowstreet Capital Limited Partnership, BlackRock Inc., Wellington Management Group LLP, Renaissance Technologies LLC, Jennison Associates LLC, Charles Schwab Investment Management Inc., and Qube Research & Technologies Ltd.
View insider buying and selling activity for Zoetis
or or view top insider-buying stocks.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $174.61.

How much money does Zoetis make?

Zoetis (NYSE:ZTS) has a market capitalization of $82.18 billion and generates $7.78 billion in revenue each year. The company earns $2.04 billion in net income (profit) each year or $4.36 on an earnings per share basis.

How many employees does Zoetis have?

Zoetis employs 12,100 workers across the globe.

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More

When was Zoetis founded?

Zoetis was founded in 2012.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for Zoetis is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at [email protected], or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.